ERBB2 and breast carcinoma: This Rollover Protocol (ROP) Study was initiated in 1998 to allow patients with HER2-positive metastatic breast cancer outside of the US, who had previously participated in Roche-sponsored HER2-positive breast cancer studies, to continue H therapy until disease progression.